Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Arvinas, Inc. - Common Stock (NQ:ARVN)

11.82 +0.38 (+3.32%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 559,743
Open 11.40
Bid (Size) 11.26 (200)
Ask (Size) 12.78 (500)
Prev. Close 11.44
Today's Range 11.30 - 11.86
52wk Range 5.900 - 20.38
Shares Outstanding 70,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff ↗
Randy Teel has been appointed as President, CEO, as well as a member of the Company’s Board of Directors, effective immediately. 
Via Stocktwits

Performance

YTD
+3.1%
+3.1%
1 Month
-1.7%
-1.7%
3 Month
-9.0%
-9.0%
6 Month
+65.5%
+65.5%
1 Year
-36.6%
-36.6%

More News

Read More
News headline image
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
From Arvinas Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Top movers in Tuesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗
Via Chartmill
News headline image
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Arvinas Inc.
Via GlobeNewswire
News headline image
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
From Arvinas Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 7 Analyst Projections For Arvinas ↗
Via Benzinga
News headline image
This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗
Via Benzinga
News headline image
Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress
From Arvinas Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 11.82
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 02/18/26 04:00 PM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 836.86M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 837M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.